StockData
Corvus Pharmaceuticals, Inc. logo

Corvus Pharmaceuticals, Inc. (CRVS) stock

CRVSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$10.17−0.43 (-4.06%)

Close on Nov 17, 2026Market cap $855.51MP/E –Yield –

Corvus Pharmaceuticals operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Corvus Pharmaceuticals's operating cash flow for the twelve months ending Jun 30, 2026 was -$44.53M. For fiscal 2025 it was -$32.80M. The highest annual figure on record is -$11.33M in fiscal 2015.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$32.80M–
FY2024Dec 31, 2024-$25.42M–
FY2023Dec 31, 2023-$23.94M–
FY2022Dec 31, 2022-$27.02M–
FY2021Dec 31, 2021-$36.72M–
FY2020Dec 31, 2020-$34.78M–
FY2019Dec 31, 2019-$37.32M–
FY2018Dec 31, 2018-$40.99M–
FY2017Dec 31, 2017-$46.21M–
FY2016Dec 31, 2016-$27.86M–
FY2015Dec 31, 2015-$11.33M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$15.40M–
Q1 FY2026Mar 31, 2026-$10.37M–
Q4 FY2025Dec 31, 2025-$9.19M–
Q3 FY2025Sep 30, 2025-$9.57M–
Q2 FY2025Jun 30, 2025-$5.78M–
Q1 FY2025Mar 31, 2025-$8.26M–
Q4 FY2024Dec 31, 2024-$8.47M–
Q3 FY2024Sep 30, 2024-$6.32M–
Q2 FY2024Jun 30, 2024-$5.48M–
Q1 FY2024Mar 31, 2024-$5.16M–
Q4 FY2023Dec 31, 2023-$5.17M–
Q3 FY2023Sep 30, 2023-$5.43M–
Q2 FY2023Jun 30, 2023-$5.22M–
Q1 FY2023Mar 31, 2023-$8.11M–
Q4 FY2022Dec 31, 2022-$7.55M–
Q3 FY2022Sep 30, 2022-$6.93M–
Q2 FY2022Jun 30, 2022-$6.12M–
Q1 FY2022Mar 31, 2022-$6.42M–
Q4 FY2021Dec 31, 2021-$6.86M–
Q3 FY2021Sep 30, 2021-$8.43M–
Q2 FY2021Jun 30, 2021-$12.65M–
Q1 FY2021Mar 31, 2021-$8.79M–
Q4 FY2020Dec 31, 2020-$8.21M–
Q3 FY2020Sep 30, 2020-$7.73M–
Q2 FY2020Jun 30, 2020-$9.49M–
Q1 FY2020Mar 31, 2020-$9.35M–
Q4 FY2019Dec 31, 2019-$8.51M–
Q3 FY2019Sep 30, 2019-$10.61M–
Q2 FY2019Jun 30, 2019-$9.21M–
Q1 FY2019Mar 31, 2019-$8.99M–
Q4 FY2018Dec 31, 2018-$8.26M–
Q3 FY2018Sep 30, 2018-$10.80M–
Q2 FY2018Jun 30, 2018-$10.89M–
Q1 FY2018Mar 31, 2018-$11.05M–
Q4 FY2017Dec 31, 2017-$10.98M–
Q3 FY2017Sep 30, 2017-$10.77M–
Q2 FY2017Jun 30, 2017-$11.71M–
Q1 FY2017Mar 31, 2017-$12.75M–
Q4 FY2016Dec 31, 2016-$9.41M–
Q3 FY2016Sep 30, 2016-$6.69M–

More Corvus Pharmaceuticals figures

See a number that looks wrong?